Physician profile
Daniel L Friedman
NPI 1134129463
$6,566.04
in general payments reported to CMS, 2019-2025
19 companies · $4,513 in 2025
The $4,513 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $88.32 · 2021: $365 · 2022: $503 · 2023: $350 · 2024: $291 · 2025: $4,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,363 · Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,362.50 |
| Food and Beverage | $790.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,362.50 | 2025 | |
| Pfizer INC. | $535.13 | 2019-2023 | |
| Glaxosmithkline, LLC. | $402.52 | 2019-2024 | Bexsero |
| Merck Sharp & Dohme LLC | $253.86 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| E.R. Squibb & Sons, L.L.C. | $241.54 | 2022-2023 | Camzyos |
| Cranial Technologies, INC | $155.22 | 2019-2025 | Doc Band |
| Kaleo, INC. | $149.83 | 2019-2024 | Auvi-Q |
| Sanofi Pasteur INC. | $101.81 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $83.00 | 2021-2024 | Flumist Quadrivalent |
| Seqirus USA INC | $53.00 | 2022-2025 | Flucelvax |
| Genzyme Corporation | $37.94 | 2021-2022 | |
| Sobi, INC | $37.65 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $37.02 | 2025 | Daybue |
| Phadia US INC. | $27.84 | 2022 | |
| Hologic Sales and Service, LLC | $19.11 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $18.47 | 2019 | |
| Corium, LLC | $16.61 | 2023 | Azstarys |
| Hikma Pharmaceuticals USA | $16.55 | 2024 | Ryaltris |
| Supernus Pharmaceuticals, INC. | $16.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.